Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines

Molecular and Cellular Endocrinology

Volumn 382, Issue 1, 2014, Pages 1-7

  Germano, Antonina ^a   Rapa, Ida ^b   Volante, Marco ^b   Lo Buono, Nicola ^b   Carturan, Sonia ^b   Berruti, Alfredo ^b   Terzolo, Massimo ^a   Papotti, Mauro ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Adrenocortical cancer; Cell lines; Gemcitabine; Mitotane

Indexed keywords

GEMCITABINE; MITOTANE;

ADRENAL CORTEX CARCINOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA CELL; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IN VITRO STUDY; MONOTHERAPY; PRIORITY JOURNAL; RRM1 GENE; UPREGULATION;

ADRENOCORTICAL CANCER; CELL LINES; GEMCITABINE; MITOTANE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; DEOXYCYTIDINE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOTANE; TUMOR SUPPRESSOR PROTEINS;

EID: 84884397988     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.08.023     Document Type: Article

References (17)

1. Bates S.E., Shieh C.Y., Mickley L.A., Dichek H.L., Gazdar A., Loriaux D.L., Fojo A.T. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J. Clin. Endocrinol. Metab. 1991, 73:18-29.
2. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K.D., Danenberg P.V., Cambieri A., Selvaggi G., Saviozzi S., Calogero R., Papotti M., Scagliotti G.V. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 2006, 17:1818-1825.
3. Cerquetti L., Bucci B., Marchese R., Misiti S., De Paula U., Miceli R., Muleti A., Amendola D., Piergrossi P., Brunetti E., Toscano V., Stigliano A. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr. Relat. Cancer 2008, 15:623-634.
4. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
5. Dackiw A.P., Lee J.E., Gagel R.F., Evans D.B. Adrenal cortical carcinoma. World J. Surg. 2001, 25:914-926.
6. Daffara F., De Francia S., Reimondo G., Zaggia B., Aroasio E., Porpiglia F., Volante M., Termine A., Di Carlo F., Dogliotti L., Angeli A., Berruti A., Terzolo M. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr. Relat. Cancer 2008, 15:1043-1053.
7. Fassnacht M., Libé R., Kroiss M., Allolio B. Adrenocortical carcinoma: a clinician's update. Nat. Rev. Endocrinol. 2011, 7:323-335.
8. Fassnacht M., Terzolo M., Allolio B., Baudin E., Haak H., Berruti A., Welin S., Schade-Brittinger C., Lacroix A., Jarzab B., Sorbye H., Torpy D.J., Stepan V., Schteingart D.E., Arlt W., Kroiss M., Leboulleux S., Sperone P., Sundin A., Hermsen I., Hahner S., Willenberg H.S., Tabarin A., Quinkler M., de la Fouchardière C., Schlumberger M., Mantero F., Weismann D., Beuschlein F., Gelderblom H., Wilmink H., Sender M., Edgerly M., Kenn W., Fojo T., Müller H.H., Skogseid B., FIRM-ACT Study Group Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 2012, 366:2189-2197.
9. Gandhi V., Mineishi S., Huang P., Chapman A.J., Yang Y., Chen F., Nowak B., Chubb S., Hertel L.W., Plunkett W. Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res. 1995, 55:1517-1524.
10. Giovannetti E., Mey V., Danesi R., Basolo F., Barachini S., Deri M., Del Tacca M. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. Br. J. Cancer 2005, 92:681-689.
11. Montoya M., Brown J.W., Fishman L.M. Comparative effects of chemotherapeutic agents on the growth and survival of human adrenal carcinoma cells in culture. Horm. Metab. Res. 2008, 40:302-305.
12. Sperone P., Ferrero A., Daffara F., Priola A., Zaggia B., Volante M., Santini D., Vincenzi B., Badalamenti G., Intrivici C., Del Buono S., De Francia S., Kalomirakis E., Ratti R., Angeli A., Dogliotti L., Papotti M., Terzolo M., Berruti A. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr. Relat. Cancer 2010, 17:445-453.
13. Stigliano A., Cerquetti L., Borro M., Gentile G., Bucci B., Misiti S., Piergrossi P., Brunetti E., Simmaco M., Toscano V. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Endocr. Relat. Cancer 2008, 15:1-10.
14. Terzolo M., Angeli A., Fassnacht M., Daffara F., Tauchmanova L., Conton P.A., Rossetto R., Buci L., Sperone P., Grossrubatscher E., Reimondo G., Bollito E., Papotti M., Saeger W., Hahner S., Koschker A.C., Arvat E., Ambrosi B., Loli P., Lombardi G., Mannelli M., Bruzzi P., Mantero F., Allolio B., Dogliotti L., Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 2007, 356:2372-2380.
15. Villa R., Orlandi L., Berruti A., Dogliotti L., Zaffaroni N. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int. J. Oncol. 1999, 14:133-138.
16. Volante M., Terzolo M., Fassnacht M., Rapa I., Germano A., Sbiera S., Daffara F., Sperone P., Scagliotti G., Allolio B., Papotti M., Berruti A. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer. Clin. Cancer Res. 2012, 18:3452-3461.
17. Wajchenberg B.L., Albergaria Pereira M.A., Medonca B.B., Latronico A.C., Campos Carneiro P., Alves V.A., Zerbini M.C., Liberman B., Carlos Gomes G., Kirschner M.A. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000, 88:711-736.